Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Hodgkin Lymphoma

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Renal Cell Carcinoma Treatment Algorithm

Video Series

KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

Videos

Rohit Gosain, MD; Rahul Gosain, MD; and Katy Beckermann, MD, PhD, discuss advances in renal cell carcinoma treatment, including adjuvant pembrolizumab following KEYNOTE-564 data, management strategies for localized disease, the impact of immunotherapy–tyrosine kinase inhibitor combination regimens for metastatic renal cell carcinoma, insights from pivotal trials, approaches to therapy sequencing, and the role of next-generation sequencing in personalized care.

Panelists discuss how recent data from the KEYNOTE-564 trial has changed their approaches to treating patients with renal cell carcinoma by implementing adjuvant pembrolizumab therapy for high-risk patients following nephrectomy, citing improved disease-free survival outcomes.

Panelists discuss how multidisciplinary approaches involving surgical resection, active surveillance, and targeted therapies have evolved in managing localized renal cell carcinoma, with consideration of tumor size, patient comorbidities, and preservation of renal function guiding individualized treatment decisions.

Localized Renal Cell Carcinoma: Current Treatment Considerations

Panelists discuss how immunotherapy–tyrosine kinase inhibitor (IO-TKI) combination regimens have revolutionized the treatment landscape for metastatic renal cell carcinoma (mRCC) by offering improved response rates, survival outcomes, and quality of life compared with traditional monotherapies.

IO-TKI Treatment Regimens in the Treatment of mRCC

Panelists discuss how recent clinical trials have shaped treatment algorithms for metastatic renal cell carcinoma (mRCC) by establishing the superiority of immunotherapy–tyrosine kinase inhibitor combinations over single-agent therapies across various risk groups.

Recent Trials Guiding mRCC Treatment

Panelists discuss how sequencing different therapies and personalizing care for their patients requires careful consideration of disease characteristics, prior treatment response, comorbidities, toxicity profiles, and patient preferences to optimize outcomes and quality of life.

Sequencing Therapies for Patients With Renal Cell Carcinoma

Panelists discuss how next-generation sequencing is transforming precision oncology by enabling comprehensive genomic profiling that identifies actionable mutations, guides targeted therapy selection, and facilitates clinical trial enrollment while acknowledging challenges in data interpretation and implementation across diverse health care settings.

Final Insights in Care for Patients With Renal Cell Carcinoma

KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

EP: 1.KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

EP: 2.Localized Renal Cell Carcinoma: Current Treatment Considerations

EP: 3.IO-TKI Treatment Regimens in the Treatment of mRCC

EP: 4.Recent Trials Guiding mRCC Treatment

EP: 5.Sequencing Therapies for Patients With Renal Cell Carcinoma

EP: 6.Final Insights in Care for Patients With Renal Cell Carcinoma

Newsletter